Affinity Asset Advisors LLC Purchases Shares of 40,000 Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Affinity Asset Advisors LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 40,000 shares of the company's stock, valued at approximately $1,609,000. Affinity Asset Advisors LLC owned 0.06% of Kymera Therapeutics as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock valued at $213,514,000 after purchasing an additional 688,967 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Kymera Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after purchasing an additional 133,546 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after purchasing an additional 95,547 shares during the period. Norges Bank bought a new position in Kymera Therapeutics during the 4th quarter valued at $3,670,000. Finally, Geode Capital Management LLC increased its position in shares of Kymera Therapeutics by 5.0% during the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock valued at $44,484,000 after purchasing an additional 52,263 shares during the period.

Analyst Ratings Changes

KYMR has been the subject of several research reports. HC Wainwright lifted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Stephens restated an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Leerink Partners reissued an "outperform" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, Citigroup assumed coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Insider Buying and Selling

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the transaction, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 in the last quarter. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Stock Up 3.8 %

Kymera Therapeutics stock traded up $0.95 during trading hours on Friday, hitting $25.97. The stock had a trading volume of 468,785 shares, compared to its average volume of 549,679. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27. The business's 50 day simple moving average is $30.47 and its 200-day simple moving average is $39.00. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -11.10 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.